Phase 2 study comparing the efficacy between afatinib & osimertinib based on immunological biomarker in EGFR-mutant NSCLC

被引：0

作者：

Morikawa, Kei ^{[1
]}

Tanaka, Hisashi ^{[2
]}

Takata, Saori ^{[3
]}

Watanabe, Satoshi ^{[4
]}

Kishi, Kazuma ^{[5
]}

Soejima, Kenzo ^{[6
]}

Kaira, Kyoichi ^{[7
]}

Kagamu, Hiroshi ^{[7
]}

Yoshimura, Kenichi ^{[8
]}

Matsutani, Noriyuki ^{[9
]}

Seki, Nobuhiko ^{[10
]}

机构：

[1] St Marianna Univ, Sch Med, Dept Internal Med, Div Resp Med, Kawasaki, Kanagawa, Japan

[2] Hirosaki Univ, Grad Sch Med, Dept Resp Med, Hirosaki, Aomori, Japan

[3] Kyorin Univ, Dept Resp Med, Sch Med, Mitaka, Tokyo, Japan

[4] Niigata Univ, Grad Sch Med & Dent Sci, Dept Resp Med & Infect Dis, Niigata, Japan

[5] Toho Univ, Omori Med Ctr, Dept Resp Med, Tokyo, Japan

[6] Keio Univ Hosp, Clin & Translat Res Ctr, Tokyo, Japan

[7] Saitama Med Univ, Int Med Ctr, Dept Resp Med, Moroyama, Saitama, Japan

[8] Hiroshima Univ Hosp, Med Ctr Translat & Clin Res, Hiroshima, Japan

[9] Teikyo Univ Hosp, Dept Surg, Mizonokuchi, Japan

[10] Teikyo Univ, Sch Med, Dept Internal Med, Div Med Oncol, Tokyo, Japan

来源：

ANNALS OF ONCOLOGY | 2022年 / 33卷

关键词：

D O I：

10.1016/j.annonc.2022.05.334

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P68-3

引用

页码：S538 / S538

页数：1

共 50 条

[31] Tepotinib plus Osimertinib in EGFR-mutant NSCLC with MET Amplification Following 1L Osimertinib: INSIGHT 2 Primary Analysis
Kim, Tae Min
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Yang, Jin-ji
Wislez, Marie
Huang, Cheng
Liam, Chong Kin
Mazieres, Julien
Tho, Ye Mun
Hayashi, Hidetoshi
Nhung Nguyen
Chia, Puey Ling
de Marinis, Filippo
Raskin, Jo
Zhou, Qinghua
Finocchiaro, Giovanna
Le, Xiuning
Tan, Daniel
O'Hara, Richard M., Jr.
Brutlach, Sabine
O'Brate, Aurora
Adrian, Svenja
Berghoff, Karin
Ellers-Lenz, Barbara
Karachaliou, Niki
Wu, Yi-Long
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E38 - E38
[32] Tepotinib plus osimertinib in EGFR-mutant NSCLC with MET amplification following first-line osimertinib: INSIGHT 2 primary analysis
Le, Xiuning
Kim, Tae Min
Guarneri, Valentina
Voon, Pei Jye
Lim, Boon Khaw
Yang, Jinji
Wislez, Marie
Huang, Cheng
Liam, Chong Kim
Mazieres, Julien
Lye Mun Tho
Hayashi, Hidetoshi
Nguyen Nhung
Chia, Puey Ling
De Marinis, Fillippo
Raskin, Jo
Zhou, Qinghua
Finochhiaro, Giovanna
Tan, Daniel
Brutlach, Sabine
O'Brate, Aurora
Adrian, Svenja
Berghoff, Karin
Ellers-Lenz, Barbara
Karachaliou, Niki
Wu, Yi-Long
MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
[33] The Difference in Clinical Outcomes Between Osimertinib and EGFR-TKI plus Anti-angiogenic Agent in EGFR-mutant NSCLC Patients
Huang, Y. H.
Hsu, K. -H.
Tseng, J. -S.
Chen, K. -C.
Chang, G. -C.
Yang, T. -Y.
JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S477 - S478
[34] Afatinib plus bevacizumab combination therapy in EGFR-mutant NSCLC patients with osimertinib resistance: Protocol of an open-label, phase II, multicenter, single-arm trial
Kobayashi, Nobuaki
Hashimoto, Hisashi
Kamimaki, Chisato
Nagasawa, Ryo
Tanaka, Katsushi
Kubo, Sousuke
Katakura, Seigo
Chen, Hao
Hirama, Nobuyuki
Ushio, Ryota
Aoki, Ayako
Nakashima, Kentaro
Teranishi, Shuhei
Manabe, Saki
Watanabe, Hiroki
Horita, Nobuyuki
Watanabe, Keisuke
Hara, Yu
Yamamoto, Masaki
Kudo, Makoto
Piao, Hongmei
Kaneko, Takeshi
THORACIC CANCER, 2020, 11 (08) : 2125 - 2129
[35] Efficacy of Osimertinib (OSI) vs 1st-Generation TKI Followed by OSI by Clinical Profile in EGFR-Mutant NSCLC (SMILE STUDY)
Auclin, E.
Du Rusquec, P.
Albarran, V.
Aboubakar, F.
Gerber, H.
Epaillard, N.
Recondo, G.
De Giglio, A.
Berthou, H.
Fabre, E.
Laguna, J. C.
Blaquier, J. -B.
Jimenez-Munarriz, B.
Tagliamento, M.
Di Federico, A.
Sacco, G.
Minatta, J.
Girard, N.
Moran-Bueno, T.
Lopez-Castro, R.
Besse, B.
Mezquita, L.
JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S344 - S344
[36] Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.
Planchard, David
Yu, Helena Alexandra
Yang, James Chih-Hsin
Lee, Ki Hyeong
Lopez, Pilar Garrido
Park, Keunchil
Kim, Joo-Hang
Lee, Dae Ho
He, Shuang
Chao, Bo H.
Paz-Ares, Luis G.
JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[37] BLU-945 monotherapy and in combination with osimertinib (OSI) in previously treated patients with advanced EGFR-mutant (EGFRm) NSCLC in the phase 1/2 SYMPHONY study
Elamin, Yasir Y.
Nagasaka, Misako
Shum, Elaine
Bazhenova, Lyudmila
Camidge, D. Ross
Cho, Byoung Chul
Felip, Enriqueta
Goto, Koichi
Lin, Chia-Chi
Piotrowska, Zofia
Planchard, David
Rotow, Julia K.
Spigel, David R.
Tan, Daniel Shao-Weng
Yoshida, Tatsuya
Minchom, Anna Rachel
De langen, Adrianus
Kato, Terufumi
Zalutskaya, Alena
Reckamp, Karen L.
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
[38] Osimertinib for patients with EGFR-mutant advanced NSCLC and asymptomatic brain metastases: An open-label, two-arm, phase II study
Gillis, R.
Peled, N.
Goldshtien, I.
Rotem, O.
Rozenblum, A. B.
Nechushtan, H.
Chen, L.
Dudnik, E.
Zer, A.
Yust-Katz, S.
Shelef, I.
Roisman, L. C.
Inbar, E.
ANNALS OF ONCOLOGY, 2019, 30
[39] MARIPOSA: Randomized Phase 3 Study of First-line Amivantamab plus Lazertinib vs Osimertinib vs Lazertinib in EGFR-mutant NSCLC
Shreeve, S. M.
Martinez, M.
Verheijen, R. B.
Xie, J.
Sun, T.
Haddish-Berhane, N.
Curtin, J. C.
Karkera, J.
Pang, D.
Roshak, A.
Knoblauch, R. E.
Patel, K.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S620 - S621
[40] RAMOSE: An Open-Label Randomized Phase II Study of Osimertinib with or without Ramucirumab in TKI-Naive EGFR-Mutant Metastatic NSCLC
Saltos, A.
Baik, C.
Sanborn, R. E.
Shum, E.
Kim, C.
Hall, R.
Fidler, M. J.
Shu, C. A.
Otterson, G.
Patel, J.
Wong, K.
Hanna, N.
Gray, J.
Heymach, J.
Le, X.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S614 - S614

← 1 2 3 4 5 →